| 臺大學術典藏 |
2020-07-21T06:09:06Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients
|
Shih J.-Y.; Ho C.-C.; Wu T.-H.;Hsiue E.H.-C.;Lee J.-H.;Lin C.-C.;Wei-Yu Liao;Ho C.-C.;Shih J.-Y.;Yu C.-J.;Yang J.C.-H.; Wu T.-H.; Hsiue E.H.-C.; Lee J.-H.; Lin C.-C.; WEI-YU LIAO; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:04Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Shih J.-Y.; Yang J.C.-H.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; WEI-YU LIAO; Chen J.-S.; Lin Y.-T. |
| 臺大學術典藏 |
2020-07-21T06:09:03Z |
Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer
|
Thress K.; Yang J.C.-H.; Stetson D.; Markovets A.; WEI-YU LIAO; Liao B.-C.; Hsu C.-C.; Hsu C.-C.;Liao B.-C.;Wei-Yu Liao;Markovets A.;Stetson D.;Thress K.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Chen K.-Y.; Tsai T.-H.; Ho C.-C.; WEI-YU LIAO; Yang C.-Y.; Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liao B.-C.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C. |
| 臺大學術典藏 |
2020-07-21T05:40:29Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Lee J.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Ching-Yao Yang;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; CHING-YAO YANG; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H. |
| 臺大學術典藏 |
2020-07-20T05:28:00Z |
Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit
|
Hsiue E.H.-C.; PEI-LIN LEE; Chen Y.-H.; Wu T.-H.; Cheng C.-F.; Cheng K.-M.; Yang P.-C.; Chen H.-W.; Lin P.-Y.; Chiang D.-L.; Wu H.-D.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:56Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Kang-Yi Su;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; KANG-YI SU; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-06-30T08:09:52Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:51Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:28Z |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations
|
Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:27Z |
Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC
|
Yang J.C.-H.; Chia-Chi Lin; Medema R.H |
| 臺大學術典藏 |
2020-05-25T07:35:25Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
Liao B.-C; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:25Z |
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
|
Kao H.-F; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:23Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S; Chia-Chi Lin; Cho D.C; Shapiro G.I; Kwak E.L; Silverman M.H; Tseng Y; Kuo M.-W; Mach W.B; Hsu S.-C; Coleman T; Yang J.C.-H; Cheng A.-L; Ghalib M.H; Chuadhary I; Goel S. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
Chia-Chi Lin; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K.; Srimuninnimit V; Ahn M.-J; Mok T; Kang J.H; Yang J.C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:20Z |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
|
Liao B.-C; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:19Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Yang J.C.-H.; Yu C.-J; Shih J.-Y; Ho C.-C; Chang C.-H; Chen Y.-F; Chia-Chi Lin; Lee J.-H; Liao B.-C |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
Liao B.-C; Chia-Chi Lin; Lee J.-H; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Profile of the therascreen? EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
|
Hsiue E.H.-C; Lee J.-H; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Safety of gefitinib in non-small cell lung cancer treatment
|
Hsiue E.H.-C; Lee J.-H; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:16Z |
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
|
Liao B.-C; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.H; Yu C.-J.; Yao Z.-H; Liao W.-Y |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
Liao B.-C; Chia-Chi Lin; Lee J.-H; Yang J.C.-H. |
